This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SNCA vs. JATT, ALVR, FNCH, AIM, NKGN, CLDI, SRNE, SQZ, GNCAQ, and GNCAShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), AIM ImmunoTech (AIM), NKGen Biotech (NKGN), Calidi Biotherapeutics (CLDI), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "medical" sector. Seneca Biopharma vs. Its Competitors JATT Acquisition AlloVir Finch Therapeutics Group AIM ImmunoTech NKGen Biotech Calidi Biotherapeutics Sorrento Therapeutics SQZ Biotechnologies Genocea Biosciences Genocea Biosciences JATT Acquisition (NYSE:JATT) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Do institutionals & insiders believe in JATT or SNCA? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 5.2% of Seneca Biopharma shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 2.1% of Seneca Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is JATT or SNCA more profitable? JATT Acquisition has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. JATT Acquisition's return on equity of -49.58% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Seneca Biopharma -230.34%-122.20%-110.61% Which has stronger valuation and earnings, JATT or SNCA? JATT Acquisition has higher earnings, but lower revenue than Seneca Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ASeneca Biopharma$10K1,034.30-$8.35MN/AN/A Does the media favor JATT or SNCA? In the previous week, JATT Acquisition had 1 more articles in the media than Seneca Biopharma. MarketBeat recorded 1 mentions for JATT Acquisition and 0 mentions for Seneca Biopharma. JATT Acquisition's average media sentiment score of 0.75 beat Seneca Biopharma's score of 0.00 indicating that JATT Acquisition is being referred to more favorably in the media. Company Overall Sentiment JATT Acquisition Positive Seneca Biopharma Neutral SummaryJATT Acquisition beats Seneca Biopharma on 8 of the 9 factors compared between the two stocks. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.34M$289.72M$5.84B$10.14BDividend YieldN/AN/A5.68%4.60%P/E RatioN/AN/A75.4125.98Price / Sales1,034.30420.31515.81181.13Price / CashN/A22.4437.5660.44Price / Book0.4510.9112.156.29Net Income-$8.35M-$111.61M$3.29B$271.07M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$0.60+2.7%N/A-84.2%$10.34M$10K0.007Gap DownJATTJATT AcquisitionN/A$2.06-6.4%N/A-44.4%$35.54MN/A0.003News CoverageHigh Trading VolumeALVRAlloVirN/A$4.68+0.9%N/A-77.5%$23.60MN/A-0.23110Gap DownHigh Trading VolumeFNCHFinch Therapeutics Group1.4039 of 5 stars$12.67flatN/A+9.7%$20.35MN/A-1.44190Positive NewsShort Interest ↓Gap DownAIMAIM ImmunoTech1.4875 of 5 stars$2.59+0.0%$275.00+10,513.7%-91.2%$7.04M$121K-5.5320Gap DownNKGNNKGen Biotech0.1402 of 5 stars$0.14+7.5%N/A-82.9%$6.41MN/A-0.03N/ACLDICalidi Biotherapeutics0.3506 of 5 stars$1.63+1.2%N/A-88.4%$5.58MN/A0.0038Short Interest ↑SRNESorrento Therapeutics0.9143 of 5 stars$0.00+80.0%N/A-22.2%$1.99M$60.32M0.00800Gap UpSQZSQZ BiotechnologiesN/A$0.03flatN/AN/A$826K$18.16M-0.011,620GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070News Coverage Related Companies and Tools Related Companies JATT Acquisition Alternatives AlloVir Alternatives Finch Therapeutics Group Alternatives AIM ImmunoTech Alternatives NKGen Biotech Alternatives Calidi Biotherapeutics Alternatives Sorrento Therapeutics Alternatives SQZ Biotechnologies Alternatives Genocea Biosciences Alternatives Genocea Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNCA) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNCA Stock Alerts